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Abstract
Background: Compared to the rest of Europe, the UK has relatively poor cancer outcomes, with late diagnosis and
a slow referral process being major contributors. General practitioners (GPs) are often faced with patients presenting
with a multitude of non-specific symptoms that could be cancer. Safety netting can be used to manage diagnostic
uncertainty by ensuring patients with vague symptoms are appropriately monitored, which is now even more
crucial due to the ongoing COVID-19 pandemic and its major impact on cancer referrals. The ThinkCancer!
workshop is an educational behaviour change intervention aimed at the whole general practice team, designed to
improve primary care approaches to ensure timely diagnosis of cancer. The workshop will consist of teaching and
awareness sessions, the appointment of a Safety Netting Champion and the development of a bespoke Safety
Netting Plan and has been adapted so it can be delivered remotely. This study aims to assess the feasibility of the
ThinkCancer! intervention for a future definitive randomised controlled trial.
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Methods: The ThinkCancer! study is a randomised, multisite feasibility trial, with an embedded process evaluation and
feasibility economic analysis. Twenty-three to 30 general practices will be recruited across Wales, randomised in a ratio of 2:1
of intervention versus control who will follow usual care. The workshop will be delivered by a GP educator and will be
adapted iteratively throughout the trial period. Baseline practice characteristics will be collected via questionnaire. We will
also collect primary care intervals (PCI), 2-week wait (2WW) referral rates, conversion rates and detection rates at baseline and
6 months post-randomisation. Participant feedback, researcher reflections and economic costings will be collected following
each workshop. A process evaluation will assess implementation using an adapted Normalisation Measure Development
(NoMAD) questionnaire and qualitative interviews. An economic feasibility analysis will inform a future economic evaluation.
Discussion: This study will allow us to test and further develop a novel evidenced-based complex intervention aimed at
general practice teams to expedite the diagnosis of cancer in primary care. The results from this study will inform the future
design of a full-scale definitive phase III trial.
Trial registration: ClinicalTrials.gov NCT04823559.




Cancer survival in the UK lags behind other western
countries [1]. Referral rates and adherence to guide-
lines are lower [2, 3], primary care providers (PCPs)
are less likely to take action on potential cancer
symptoms [4] and cancer tends to be diagnosed at a
later stage, often only after patients have presented
to acute or emergency secondary care services [3].
Compared with the rest of Europe, the UK has rela-
tively low 1-year survival, which could be due to later
diagnosis [5].
Timely diagnosis is key to improving cancer outcomes
[6] and cancer survival [7]. Earlier diagnosis could also
reduce the proportion of cancer patients diagnosed
through emergency care [7]. Early diagnosis is a rising
priority in cancer policy [6, 8], because it is cost-effective
[1] and the incidence of cancer is increasing [9]. Policies
in Wales emphasise the importance of early diagnosis
and recognise that increasing demand and a slow referral
process are significant barriers to a quick cancer diagno-
sis [3]. Following the implementation of these policies,
progress has been slow, with late stage diagnosis con-
tinuing to be an issue [10].
The timely diagnosis of cancer has become even more
relevant as we enter a period in which primary care and
cancer management have changed dramatically due to
the ongoing COVID-19 pandemic [11–13]. Early figures
have shown a 76% decrease in urgent cancer referrals
across the UK and predict a 20% increase in excess
deaths for patients with newly diagnosed cancers [14].
The increased use of remote consultation as a result of
the pandemic will have implications for the early diagno-
sis of cancer, as important consultation techniques such
as the use of visual cues and physical examination [15]
may be impacted.
Primary care providers (PCPs) play a vital role in the
early diagnosis of cancer [16]. A key diagnostic stage is
the Primary care interval (PCI), which is the time from
first presentation to a GP with a symptom that could be
cancer, to the subsequent referral to a specialist in sec-
ondary care [17]. However, with an ever expanding role,
PCPs are presented with a plethora of non-specific
symptoms, of which only a small proportion are caused
by cancer, and many overlap with other diseases [6].
Furthermore, with certain cancers, patients may not
present with any alarm symptoms [6, 16] which often re-
sults in a delayed cancer diagnosis [2]. In addition,
guidelines to expedite early cancer diagnosis are often
unclear, with great variation in strategies between differ-
ent GPs [18].
Rationale and previous work
This study comprises work package 4 of the Wales In-
terventions for Cancer Knowledge and Early Diagnosis
(WICKED) programme. Work package 1 consisted of a
review of reviews and a realist review, Work Package 2
comprised qualitative interviews with 20 GPs, four focus
groups with primary care practice staff, and a combined
quantitative survey and Discrete Choice Experiment
(DCE), sent to GPs in Wales. The data garnered from
work packages 1 and 2 fed into the development of the
intervention (work package 3) via the Behaviour Change
Wheel (BCW) [19]. A target behaviour was identified—
GPs thinking of and acting on clinical presentations that
could be cancer—and through application of the BCW,
education and training, enablement and restructuring of
the environment were selected as intervention functions.
The findings of the earlier work packages and the devel-
opment of the intervention are described in more detail
elsewhere [20].
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Clinical behaviour change interventions targeting PCPs
have the potential to address barriers to suspected can-
cer identification and referral and could expedite the
diagnosis of cancer and improve cancer outcomes over-
all [21]. Behaviour change at PCP level can be achieved
through various mechanisms, including feedback, elec-
tronic prompts and training [22–24]. Financial incen-
tives have also been found to be effective, but once
withdrawn may lead to a drop in the quality of care [25].
There is some evidence that educational interventions
targeted at PCPs could reduce the PCI, providing they
encompass a multidimensional, interactive and tailored
approach [21, 26, 27]. A recent systematic review of pri-
mary care interventions suggested that a whole-practice
approach providing opportunities for peer review and
feedback could have a positive effect on referral
practices, in addition to existing guidelines being revis-
ited through training and reinforcement [28]. This was
also confirmed by the findings of the qualitative work in
the previous WICKED work packages, where GPs
highlighted positive practice culture and a whole-
practice approach as important themes [20].
While the timely diagnosis of cancer is crucial, urgent
referral can lead to over-diagnosis and over-investigation
which can be harmful to the patient [7, 29]. This risk is
especially high if the patient presents with vague symp-
toms [30]. Safety netting, a tool used to manage diagnos-
tic uncertainty [31], can address these issues by ensuring
that patients with non-specific symptoms are not ig-
nored [29, 32]. Instead of immediate referral, patients
are monitored according to a set step-wise investiga-
tional plan, while ensuring they are referred in a timely
manner as and when required [29, 32]. Although safety
netting is currently recommended by national guidelines
[33], there are no clear recommendations on how to do
it [18, 29, 31, 32].
In summary, it is relevant and befitting to develop and
test interventions aimed at improving the quality and
consistency of primary care approaches to ensure timely
diagnosis of cancer in the UK. This will require multi-
component and complex behavioural change interven-
tions, which utilise a multidimensional, interactive,
tailored, whole-practice approach.
The ThinkCancer! intervention is a complex behaviour
change intervention aimed at general medical practice
teams. It consists of a multi-component workshop that
includes educational early diagnosis and awareness ses-
sions, evaluation of current practice-based safety netting
systems and the appointment of a safety netting cham-
pion. The workshop will be led by an educational facili-
tator who will guide the development of a bespoke safety
netting plan for each practice.
The aim of this study is to assess the feasibility of de-
livering the ThinkCancer! intervention and conducting a
future, definitive randomised UK-wide controlled trial
(RCT) to assess effectiveness and cost-effectiveness, in
order to establish whether the intervention can be rolled
out in practice.
Study objectives
The objectives of this study are as follows:
1) To assess the feasibility of a future definitive RCT
by monitoring recruitment and retention, outcome
measure completion and reasons for decline.
2) To assess the acceptability, feasibility, and utility of
the ThinkCancer! intervention as a whole and of
each of its individual components, and refining the
intervention as necessary.
3) To determine the most feasible and appropriate
primary outcome measure for a definitive RCT and
producing means and confidence intervals for
calculating effect sizes for the design of a definitive
trial.
4) To describe current contextual differences, and
similarities, between general medical practices and
their usual safety netting practices.
5) To identify and test the methods and outcome
measures for a process evaluation of a future
definitive RCT.
6) To undertake a feasibility analysis of the most
appropriate approach for an economic evaluation
alongside a future definitive trial.
Methods
Study design
This feasibility study incorporates a pragmatic, multisite,
two-armed, superiority, pilot RCT. There is an embed-
ded process evaluation and feasibility economic analysis.
The unit of randomisation is the general medical prac-
tice, and the primary clinical outcome is collected at the
practice level.
The term ‘feasibility’ is used in accordance with the
conceptual framework developed by Eldridge and col-
leagues [34], where it is described as an umbrella term
within which pilot trials are a component. Furthermore,
the study has been designed in accordance with the
MRC Framework for evaluating complex interventions
[35]. The trial will be conducted according to NIHR
guidance [36] and recommendations for good practice in
pilot studies [37].
The process evaluation, which will be based on a
mixed-methods approach, will follow the MRC guidance
for process evaluations of complex interventions [38].
During the initial piloting or feasibility testing stage of
an intervention, process evaluation has a vital role in
understanding and planning the future potential
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implementation of the intervention and optimising its
design and evaluation [38].
The feasibility economic analysis will explore the ap-
propriate future perspective of analysis, most appropriate
methods of gathering costs, and range and value of out-
come measures and undertake a feasibility budget im-
pact analysis of the ThinkCancer! intervention developed
through a range of blended methods that it is delivered
online (either in a live format or pre-recorded) or face-
to-face in general practices across north Wales.
This study protocol was developed in line with the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines [39]; the SPIRIT
checklist (Appendix 1) and the schedule of procedures
can be seen in Table 1. The SPIRIT checklist has been
adapted in accordance with the CONSORT extension to
pilot and feasibility trials [40].
Study setting
The setting for this study is primary care. The interven-
tion will be delivered in-practice or online to individual
general medical practices and incorporates a whole-
practice approach. The trial will be conducted across
Wales and practices will be recruited from all seven
Welsh health boards.
Intervention
The proposed intervention, the ThinkCancer! workshop,
has four chief components. The first are two educational
sessions, one for all clinical staff (the ‘early diagnosis’
session) and one for non-clinical but patient-facing staff
(the ‘cancer aware’ session). The early diagnosis session
is delivered as a teaching seminar with learning out-
comes focussed on NICE NG12 Suspected Cancer: rec-
ognition and referral guidelines [27], hot topics
exploring the harder to recognise cancer presentations
and consultation-level safety netting. As a proposed aid
to support and formalise safety netting, a new tool—the
Shared Safety Net Action Plan (SSNAP) [41] will be in-
troduced. The SSNAP tool is a co-produced patient-
facing information leaflet that can be used by a clinician
to give specific safety netting advice to a patient about
when and how they should re-present for further med-
ical assessment [41]. This tool can be used in support of
patients who present with ‘low risk, but not no risk’
symptoms or in situations where it would be too soon to
trigger an urgent referral or diagnostic investigation.
Proposed benefits of the tool include increasing patient
empowerment to navigate primary care systems in gain-
ing follow-up appointments, and by keeping copies of
the tool within the patient record, better record advice
and guidance given. This session will also see the intro-
duction of the ThinkCancer! handbook, which will con-
tain all the resources used in the workshop as well as
external resources regarding early diagnosis and safety
netting, such as NICE guidance and online learning re-
sources. The cancer aware session is less formal with
more convenor-led discussion around cancer red flag
symptoms that non-clinical staff may encounter. The
secondary aim of this session is to gauge and explore is-
sues and norms around raising concerns within the
practice team. The third session (the ‘safety netting ses-
sion’) involves the two final components of the interven-
tion, the co-production of a bespoke Cancer Safety
Netting Plan (CSNP) and appointment of a Cancer
Safety Netting Champion (CSNC). This session is
attended by a combination of clinical and administrative
staff who will be involved in the design and implementa-
tion of a new plan. The CSNP will evolve from discus-
sions built on three components, learning from the
earlier educational parts of the workshop, evaluation of
the current practice safety netting systems reported in
the practice questionnaire and the attendee’s personal
reflections of cancer diagnosis and safety netting. Fol-
lowing this discussion, a summary document highlight-
ing potential new action points will be sent back to the
practice for them to take forward and develop. Success
in developing and implementing a new practice plan
may be increased by the appointment of a champion to
drive change and therefore the appointment of a CSNC
is explored during this part of the workshop.
Members of the research team will deliver the inter-
vention; the GP Educator (AS) will oversee the work-
shop, supported by up to two researchers. The
workshop was originally designed to be delivered face-
to-face in participating practices during practices’ allo-
cated protected time for educational and professional
development. However, due to the ongoing COVID-19
pandemic, the workshop has been adapted into a digital
format and can be delivered in one of three ways: (i)
fully remote and live via online conferencing platforms;
(ii) blended delivery, where practices are offered a com-
bination of pre-recorded versions and live remote deliv-
ery of the different sessions; and (iii) face-to-face in the
practice, as originally intended, if the situation allows.
Practices that opt for the blended delivery of the work-
shop can choose to receive pre-recorded videos of ses-
sions 1 and 2, presented by the GP Educator, allowing
participants to engage with the materials in their own
time. The final session, which focuses on the Cancer
Safety Netting Plan, will still need to be delivered as a
live session due to its interactive components. There will
be flexibility to work with the practice to allow the be-
spoke design of the workshop format to improve the
reach of the intervention. Practices receiving the inter-
vention in any of the remote forms will be sent all of the
workshop materials, including the handbook and SSNAP
tool, via post. If there is the possibility to deliver the
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Table 1 SPIRIT protocol schedule of procedures for the ThinkCancer! study
Disbeschl et al. Pilot and Feasibility Studies           (2021) 7:100 Page 5 of 17
workshop face-to-face, materials will be distributed in
the practice at the beginning of the workshop. Practices
randomised to the control group may also receive the
pre-recorded videos at the end of the study period, along
with the intervention materials.
A logic model (Fig. 1) has been developed to describe the
intervention components and how they link to the intended
outcomes and will be adapted throughout the study period.
The previous work packages of the WICKED programme
have involved extensive work with primary care staff
throughout, which has directly fed into the development of
the intervention. GPs were the focus and source of data col-
lection in the early work packages and have been involved in
the refinement of the intervention via a small pilot of the
workshop in a general practice local to the research team. In
addition, we have had a member of the public actively in-
volved from the very beginning of the project, who coopera-
ted with the team in developing the intervention and the
trial protocol.
Outcome measures
The outcomes that will be reported in this feasibility
study are as follows:
Recruitment will be assessed quantitatively by captur-
ing the numbers of practices
▪ Approached
▪ Interested in participating
▪ Consented
▪ Randomised
A description of the excluded practices will be in-
cluded to help identify potential future eligibility criteria
and reasons for non-participation will be sought.
Retention will be assessed quantitatively by the numbers of
practices providing both baseline and follow-up data.
Data on individual practice characteristics will be col-
lected to:
▪ Describe the studied sample
▪ Identify potential effect modifiers
▪ Allow identification of ‘usual practice’
The overarching goal of the ThinkCancer! intervention
is to change GPs’ and primary care practices’ behaviours
and systems, encouraging them to be more cancer-aware
Fig. 1 ThinkCancer! logic model
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and act sooner on clinical presentations that could be
cancer, or more effectively safety net cases where con-
cern exists but criteria for immediate referral are not
met. The proposed primary clinical outcomes for the de-
finitive RCT relate to the early referral of suspected can-
cer. They include the 2-week wait (2WW) referral rate
and the PCI. The 2WW referral rate is defined as the
crude rate of 2WW referrals multiplied by 100,000 and
divided by practice list size [42]. The PCI is defined as
the time between the date of first presentation and the
date of referral [17].
Secondary clinical outcome measures include the
conversion rate and the detection rate. The conver-
sion rate is defined as the ‘proportion of 2WW refer-
rals that are subsequently diagnosed with cancer’ [42]
and the detection rate consists of the ‘proportion of
new cancer cases treated who were referred through
the 2WW route’, [42] also known as the sensitivity
[43]. These measures will allow us to further explore
potential clinical outcomes.
Although it is unlikely that we will detect a difference
in the clinical measures in the feasibility study due to
the small sample and short duration of follow-up, we do
expect these outcome measures to be affected by the on-
going COVID-19 pandemic. However, the feasibility of
using these outcomes will be assessed.
The feasibility of using potential clinical primary out-
comes, 2WW referral rate, PCI, conversion rates, and
detection rates will be assessed quantitatively by
determining:
▪ Ability to collect/capture data from the practices,
based on completion rates of data collection forms
▪ Ability to extract relevant data from routinely
collected data at Health Board level and from
individual practices, based on whether we are able to
obtain the data via Health Board contacts and whether
these data are comparable with those collected by
individual practices
▪ Suitability and variability of the data to perform as
primary outcome measures for clinical effectiveness
Acceptance, adherence to and fidelity of the interven-
tion will be assessed by:
▪ Reviewing participant views, reflections and
perceptions expressed via post-workshop feedback
forms and interviews
▪ Post-workshop reflections from the intervention deliv-
ery staff
▪ The ability to organise/schedule and deliver
workshops
▪ The number of practices that actively nominate a
safety netting champion
▪ The number of practices that demonstrate the use of
the safety netting plan
To inform the process evaluation for the future defini-
tive trial, we will do the following:
▪ Evaluate how to scale up for any future process
evaluation,
▪ Determine the acceptability and appropriateness of
the interview process
▪ Identify barriers and facilitators to successful
implementation,
▪ Test measures for assessing reach, dose and fidelity of
the intervention
For the health economics component, we will do the
following:
▪ Determine the feasibility of collecting data relating to
the costing of the intervention via costings forms
▪ Identify variables necessary for the design of a future
economic evaluation alongside a definitive trial
▪ Review relevant literature on the cost-effectiveness of
online and mixed-methods Continuing Professional De-
velopment (CPD) programmes for health professionals
in a community setting
▪ Consult the DIRUM database [44] to identify the
most appropriate way of capturing the costs of the
ThinkCancer! intervention (online delivery and mixed-
methods delivery)
Adaptations to the intervention and logic model will
also be recorded throughout the trial period.
Progression criteria
The outcome measures relating to recruitment, reten-
tion and adherence/fidelity will be assessed using RAG
criteria, as defined below:
1. Confirmation of adequate recruitment for a
definitive trial at practice level. Go: 20 or more
general medical practices recruited; Review: 15–
19 recruited; Stop: < 15 practices recruited.
2. Confirmation of adequate retention for the
definitive trial at practice level. Go: 80% or more
practices retained; Review: 65–79% practices
retained; Stop: < 65% practices retained
3. Confirmation of adequate fidelity of the
intervention. Go: 80% or more of all intervention
sessions delivered, Review: 50–79% of all
interventions delivered; Stop: < 50% of interventions
delivered.
4. Confirmation of adequate fidelity at individual
practice staff level: From each general practice:
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a. At least 50% of the clinical staff should attend
the workshops;
b. At least 50% of the administrative staff should
attend the workshops, comprising at least 50%
of the reception and secretarial staff as well as
the practice manager.
c. Staff who do not attend the training should
have the information cascaded to them by a
member of the team who did attend the
training. At least 75% of the staff should receive
the training either directly or indirectly.
Progression criteria relating to obtaining data regard-
ing completion of outcome measures will be assessed
using the following progression criteria:
1. Routine data. Go: data from 70% or more practices
obtained; Review: data from < 70% of practices
obtained
2. Individual data. Go: data from 70% or more of
individuals of each practice obtained; Review: data from
< 70% of individuals from each practice obtained
These criteria would reflect the potential outcomes for
exclusion/inclusion at a full definitive trial stage rather
than prevention of the study progressing.
Sample size
We aim to recruit 23–30 general medical practices. As
the intention is to have a minimum of 15 practices ran-
domised to the intervention, it was determined that a
minimum of 23 practices would be needed to provide
sufficient data for the trial and to allow for development
of the intervention. The maximum that was considered
possible to recruit is 30 practices. Practices will be ran-
domised using a randomisation allocation ratio of 2:1 of
intervention versus control. Randomising in preference
to the intervention will allow us to iteratively develop
the intervention more effectively.
As this is a feasibility study, there is no requirement for a
formal power calculation. This study is not intended to be
powered to identify a clinically meaningful difference be-
tween the intervention groups for the primary outcome mea-
sures, rather this study aims to provide robust estimates for
the likely recruitment and retention rates and give an indica-
tion of the potential variability in the proposed outcome
measures, which will in turn be used to inform the power
calculation for a future definitive RCT. This is discussed fur-
ther under statistical analyses.
Recruitment and consent
Recruitment
General practices will be identified through contact de-
tails publicly available via practice websites and through
contact lists provided by the health boards across Wales.
Practices will be invited to participate using a standar-
dised invitation via email addressed to the practice man-
ager, along with information about the study. Practice
managers will be asked to consult with their team and
indicate their interest in participating in the study by
responding to the email. They will also need to advise of
their practice’s availability for potential workshop dates.
If no response to the initial email is received, a re-
minder email will be sent followed by a telephone call. A
participant flow diagram can be seen in Fig. 2.
Practices that take part in the study will be financially
reimbursed for their time; the reimbursement amount
was decided upon based on input from local GPs. In
addition, participants will receive a copy of the interven-
tion handbook that includes the NG12: Suspected can-
cer: recognition and referral summary tables, and
certificates of attendance. Staff members involved in the
design and implementation of a new cancer safety net-
ting plan can consider using this as the basis of a quality
improvement project for revalidation and appraisal pur-
poses. Educational accreditation of the workshop will be
sought for a future main trial.
We are aware that some challenges in the recruitment
lay ahead, but we plan to work with the various research
infrastructures in Wales to overcome this. We plan to
work closely with the Primary Care Specialty Lead and
Primary Care Research Managers within Health and
Care Research Wales, and we will establish contacts
within regional primary care clusters, with health board
staff and with R&D departments in order to maximise
potential recruitment opportunities. We will also work
closely with the practices that agree to take part in order
to support their participation in the study. The recruit-
ment methods will be continually assessed and itera-
tively developed to determine the most appropriate
recruitment strategy for a future definitive RCT.
Eligibility to participate
As feasibility is the main objective of this study, all types
of general medical practice will be eligible for inclusion.
This will aid intervention refinement and allow for a bet-
ter understanding of what is feasible across a range of
practices and also why some practices may not be able
to take part.
Inclusion
Any general practice in Wales is eligible for inclusion.
The target audience for the intervention, based on a
‘whole team approach’, includes all practice staff mem-
bers. These may include, for example, GPs, nurse practi-
tioners, nurses, health care support workers (HCSWs),
practice managers, administrators, receptionists or any
other practice staff, clinical and non-clinical. We would
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aim to include any new forms of primary care organisa-
tions such as managed GP practice networks or other
general medical practice amalgamations, as well as trad-
itional GP partnerships. However, some of these may be
unstable practices with no regular GP staff, and as such,
they may be difficult to recruit or find it difficult to par-
ticipate. Practices participating in other research are also
eligible for inclusion; they will be asked to notify us of
any cancer-related studies they may be participating in
via the baseline questionnaire.
Fig. 2 Participant flow diagram
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Exclusion
There are no exclusion criteria.
Consent
Practice managers will be sent more detailed study infor-
mation in the form of a ‘Research Information Sheet for
Practices’ (RISP) and a link to an online baseline practice
questionnaire after they have expressed an interest to
take part in the study. Participating practice managers
will need to indicate that they have read the study infor-
mation and have agreed with consent statements on the
first page of the electronic questionnaire before they can
proceed. Prior to the commencement of the ThinkCan-
cer! workshop, Participant Information Sheets (PIS) will
be provided by members of the research team and writ-
ten consent will be obtained from all participating mem-
bers of staff. This will include consent to use
anonymised data recorded on paper or audio-file during
workshops and workshop feedback forms. At this time
point, participants will also be given the option to pro-
vide their contact details should they be happy to be
contacted for a telephone interview. Those who indicate
that they would like to take part will be contacted at
least 2 months after the intervention. Participants from
practices randomised to the control arm, who do not
take part in a workshop, will also have the opportunity
to take part in a telephone interview and will be sent an
invitation letter via their practice manager. Response to
interview invitations and supplying of contact details will
be taken as consent to be contacted and informed con-
sent will be obtained verbally at the time of interview.
Although we will initially contact practice managers,
and they will most likely be the person who completes the
questionnaire, this task may be delegated to another
member of the practice team with a particular interest in
the study.
Pre-trial pilot
A local practice, known to the research team, has agreed
to participate in a ThinkCancer! pilot workshop prior to
full rollout of the feasibility study. The practice is an
urban, large 12,000 patient training practice in a moder-
ately deprived region of North East Wales. Data will not
be collected or recorded for trial purposes and feedback
from those participating will only be used to refine the
intervention prior to its delivery across recruited
practices.
Randomisation and blinding
The general medical practice will be the unit of random-
isation. Randomisation will be achieved online, through
the remote randomisation centre at the North Wales
Organisation for Randomisation Trials in Health
(NWORTH) at Bangor University. The randomisation
system will use a dynamic adaptive allocation algorithm
[45] to achieve randomisation, stratified for health board.
ThinkCancer! is an open trial where blinding of partici-
pants, researchers and the statistician is not possible due
to the nature of the intervention and 2:1 ratio for
randomisation.
Withdrawal criteria
Practices (and individuals within a practice) will be free
to withdraw from the trial at any time, and their right to
refuse participation will be respected throughout. We
will seek to understand their reasons where possible. In
terms of the primary outcome measures, as long as it is
possible to collect the data, intention-to-treat analysis
will be utilised, whether or not the intervention was re-
ceived or adhered to.
Data collection
The feasibility study will be used to rehearse data collec-
tion approaches and assess their ease of use. Data will be
collected at time-points specific to each item and de-
pending on the type of data. All data collected in this
study will be anonymised.
Proposed clinical effectiveness outcomes
Data relating to the proposed primary outcomes for the
future definitive RCT will be collected at baseline and 6
months after randomisation. Two-week wait referral
data and PCI data will be collected directly from partici-
pating practices via Case Report Forms containing full
instructions on how to extract the data from practice IT
systems. We will work with the Practice Manager, CSNC
or other delegated individuals to achieve this. It is recog-
nised that this is likely to be too short a follow-up period
for meaningful differences to be observed, but the main
purpose in this case will be to test the feasibility of col-
lecting the data in this way. Additionally, we will explore
the availability of 2WW data at health board level.
Practice questionnaires
The baseline and endline practice questionnaires will be
available online to both intervention and control prac-
tices and are to be filled out by the practice manager or
other designated person, ideally in collaboration with the
practice team; SurveyMonkey™ will be the most likely
platform. The questionnaires will consist of closed ques-
tions and some open, free-text questions, and will be
used to collect data for each individual practice on the
practice characteristics and current systems, and existing
practice systems relating to cancer diagnosis and safety
netting. The baseline data may be used to inform some
workshop planning—i.e. workshop content and delivery
may be tailored to some extent to suit individual prac-
tice needs and circumstances. Further process evaluation
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data will also be collected from the practice question-
naires as they will incorporate questions exploring con-
textual factors known to influence the success of quality
improvement approaches used to improve health care
[46]. The baseline questionnaire will be completed by all
practices prior to randomisation. The endline question-
naire will assess any differences in practice, knowledge
or systems in comparison with those measured at base-
line and will be completed at 6 months post-
randomisation.
Baseline measures will include the following:
▪ Demographic information and practice characteristics
(practice size, research-accredited status, number of
clinical and non-clinical staff members, whether a
teaching practice, etc.)
▪ Practice culture (e.g. team structure, diversity of team
member roles, team decision-making processes)
▪ Practice knowledge with regard to safety netting and
cancer awareness
▪ Current safety netting systems in place, if any,
including:
○ What systems are in place
○ How widely they are used within the practice
○ How safety netting issues are communicated:
▪ Between clinicians
▪ To the wider practice team
▪ To patients
○ How safety netting is recorded
Feasibility and piloting data
Recruitment, retention and questionnaire completion
numbers will be recorded throughout the trial. Spread-
sheet systems will be put in place to record practice re-
sponses and to track their progress in the trial (e.g.
number of practices approached, whether they have
responded to the initial invitation, whether they have
agreed to be randomised, etc.). Separate spreadsheets
will also record feasibility data relating to the workshop
itself, such as participant numbers.
Post-workshop reflections and participant feedback
Data specific to the intervention will be collected via
participant feedback and observation and reflections
of the research staff. Participant feedback forms will
be distributed to practice staff; these can be com-
pleted in paper format or online. Responses will be
requested using a combination of Yes/No choices,
Likert scales and free-text comments. The questions
will cover a number of areas including acceptability,
usefulness, learning outcomes and the potential to
change practice [47].
Relevant ad hoc communications with practices
throughout the study will also be collected on a
spreadsheet, which may contribute to understanding the
intervention in terms of what works, why and how.
The same research team members will deliver the
intervention in all practices; their observations will be
collected and will inform any refinements of the inter-
vention. Observations and reflections recorded by the re-
search team may provide valuable data on the potential
effects of contextual factors, site-by-site and component-
by-component measures, and the appropriateness of in-
dividual questions included in the practice question-
naires. They will also describe the cancer safety netting
plan proposed by the practice and whether the SSNAP
tool is used.
The researchers will keep a diary, which will include a
record of any modifications made to the intervention
and data collection methods.
Health economics
Health economics data collection sheets will be com-
pleted by the researchers following each workshop, and
costings specific to the practice will be recorded. We will
also use the feedback forms to determine staff roles
within the practice for costing purposes.
NoMAD instrument
At least 2 months after the intervention, participants
who consented to be contacted will be sent a link to
complete an adapted Normalisation Measure Develop-
ment (NoMAD) instrument [48]. This will assess the im-
plementation of the cancer safety netting plan using
Normalization Process Theory (NPT) principles, which
may or may not include the SSNAP tool depending on
uptake.
Telephone interviews
We will conduct qualitative telephone interviews lasting
up to 30 min with a purposive sample of up to 45 clin-
ical and non-clinical practice staff. Practice staff in both
arms of the trial will be eligible to participate in the in-
terviews as they will be invited to give feedback on all as-
pects of the trial process including the intervention
where appropriate. The qualitative interviews are de-
signed to achieve an in-depth understanding of the views
and perceptions of practice staff involved in the trial.
The interviews will allow participants to explain how
they were able to utilise aspects of the trial and how they
worked in practice. Informed consent will be obtained
and interviews recorded and transcribed verbatim. The
interviews will be semi-structured and will follow a pre-
defined topic guide, although not every participant will
be engaged with every section of the topic guide (i.e.
only the specific areas of the topic guide that are rele-
vant to an individual’s role and experience will be ex-
plored). Topics may include acceptability, safety netting,
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data collection, uptake of the intervention and SSNAP
tool and implications. These interviews will occur at
least 2 months after the intervention has taken place;
control practices will be invited two months post-
randomisation.
Adverse events
A risk assessment has found this trial to be low risk. Par-
ticipating practices are encouraged to report any adverse
events. The Chief Investigator (CI) will determine
whether they are Adverse Events (AEs) or Serious Ad-
verse Events (SAEs). They will be reported in line with
current ICH-GCP Standard Operating Procedures [49].
SAEs are defined as follows:
…an untoward occurrence that (a) results in death; (b)
is life-threatening; (c) requires hospitalisation; (d) results
in persistent or significant disability or incapacity; (e)
consists of a congenital anomaly or birth defect; or (f) is
otherwise considered medically significant by the investi-
gator [49]
We do not expect any related SAEs for this study.
Data analysis
Quantitative analysis
A fully documented statistical analysis plan will be pre-
pared by NWORTH, a registered clinical trials unit, and
agreed by the co-investigators and approved by the trial
governance structure, which will be known as the Trial
Steering Committee (TSC). The statistical analysis plan
will be approved prior to data collection being completed.
Baseline characteristics will be summarised for all
practices, the intervention group and control groups
separately. Feasibility and process evaluation data such
as practice recruitment rate, implementation and uptake
of and adherence to the intervention, and follow-up
rates will be summarised and presented as percentages.
Determining differences in clinical outcomes between
the control and intervention is not the primary purpose
of this study; therefore, the focus of the results will be
on the estimates of the treatment effects rather than
statistical significance and as such, no hypothesis testing
will be undertaken. As recommended in guidelines for
good practice for the analysis of pilot studies [37], sum-
mary estimates of effects will be developed along with
their 95% confidence intervals. Differences between the
two comparison groups will be presented in the form of
an unadjusted mean difference for continuous outcomes,
and an odds ratio for binary outcomes. Exploratory ana-
lysis using ANCOVA for continuous outcomes and lo-
gistic regression for binary outcomes will consider
adjustment for the stratification variables in assessment
of the treatment effects.
Factors associated with the ability to implement the
intervention will be tentatively explored using logistic
regression with the focus on identifying deterministic
barriers to implementation rather than probabilistic fac-
tors. The nature of the intervention may vary, directed
by real-time feedback during the course of the trial, and
this will need to be taken into consideration during
analysis.
As this is a feasibility study, there will be no imput-
ation of missing data over and above any scoring rules
established for the outcomes. This information will be
used to feed into the suitability and applicability of the
chosen outcome measures.
Economic analysis
Alongside the statistical analysis plan, a Health Economics
Analysis Plan (HEAP) will be produced setting out the ob-
jectives and methods for data collection and analysis of
the health economics findings [50]. The HEAP will be
signed-off by the lead health economist and CI prior to
any data being shared with the health economics re-
searchers. From a NHS perspective, a micro-costing
approach will be used to gather sufficient economic data
to cost the ThinkCancer! intervention through the use of
health economics data collection sheets. In micro-costing,
each component of resource use is estimated and then a
unit cost is derived using 2019 national reference costs (in
Great British Pounds Sterling) where available [51–53]. In
addition and separately, the costing of the development of
the ThinkCancer! intervention will include researcher
time, piloting, materials development, printing, publica-
tion, development of online materials, etc. Delivery costs
of the ThinkCancer! intervention will be determined based
on the following:
▪ Online delivery format—live seminars/webinars, staff
time and materials, exploration of whether health
professional time should be collected in a full trial to
reflect the co-production nature of CPD in own time
or reflecting the opportunity cost of CPD in terms of
time not spent on direct patient care activities.
▪ Mixed-format delivery—potential costs of a face-to-
face/online delivery format across Wales in future after
COVID-19.
Qualitative analysis
The transcribed telephone interviews, the free text re-
sponses from the feedback forms and the observational
data, in text form, will be analysed for the process evalu-
ation using Framework Analysis [54]. Framework is a
five-stage matrix-based system for analysing qualitative
data which is highly appropriate for a feasibility study
which is iterative in its development. Initially, all tran-
scripts and textual data will be read thoroughly by the
same researcher who conducted the interviews to
achieve data familiarisation and immersion. An index of
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emergent themes will then be created and data coded
according to the index. Charts will be created according
to the themes and coded data will be synthesised into
the appropriate thematic charts. The completed charts
will then be used for final stage which is in-depth inter-
pretation [54].
Trial management
The Sponsor is Bangor University. The study will be
supported by the North Wales Organisation for Rando-
mised Trials in Health (NWORTH), which is a fully reg-
istered Clinical Trials Unit.
There will be no on-site monitoring as there are no
local research teams at sites. Therefore, the monitoring
of data will have a more internal focus in the form of
self-audits to ensure compliance with regulations.
Trial governance
Operational group
The operational working group will be responsible for
the overall conduct, supervision and progress of the
study. They consist of the immediate research team, sup-
ported by a wider group of experts.
Trial management group
The trial management group (TMG) will meet once a
month, consisting of the operational group and a wider
team of experts, including a PPI member. The group will
be responsible for the overall management of the trial
and ensuring the study adheres to the protocol.
Trial governance structure
A Trial Steering Committee (TSC) committee will pro-
vide independent oversight for the study, ensuring it is
conducted according to the standards set out by the
HRA Research Governance Framework [55]. As the
study includes an element of ongoing intervention re-
finement and is deemed low risk with very minimal like-
lihood of stopping early due to patient safety, a Data
Monitoring and Ethics Committee (DMEC) will not be
required [56].
Meetings are expected to be biannual and the Sponsor
and Funder will be updated following each meeting. The
TSC will have an independent chairperson (Aneez
Esmail) and at least three independent members includ-
ing Patient and Public Involvement (PPI) representation,
trial co-applicants, a statistician (Rhian Gabe), a health
economist (Laura Ternent) and other independent
members.
Data management
A detailed data management plan will be written by
NWORTH staff and approved as soon as possible fol-
lowing commencement of data collection, if not before.
This plan will include the definition of the data quality
checks that will be performed on the data throughout
the life course of the trial. These will include source data
validation, random data checks and timelines for data
entry.
Quality control
Quality control will be maintained through adherence to
the study protocol, Betsi Cadwaladr University Health
Board/Bangor University Standard Operating Procedures
(SOPs), principles of Good Clinical Practice, research
governance and clinical trial regulations.
Data protection and participant confidentiality
All investigators, trial site and research staff will comply
with the requirements and regulations of the EU General
Data Protection Regulation 2018 (GDPR) regarding the
collection, storage, processing and disclosure of personal
information and will uphold the Regulation’s core prin-
ciples. All research staff involved will have up to date
GCP training. Research data will be retained as per the
Sponsor’s research data management policy. Bangor
University is the data custodian.
Data archiving
As per the Sponsor’s research data management policy,
research data and records will be archived along with
the data management policy of the Sponsor.
In line with legal requirements, trial documents will be
archived centrally at a secure facility with appropriate en-
vironmental controls and adequate protection from fire,
flood and unauthorized access. Archived material will be
stored in tamper-proof archive boxes that are clearly la-
belled. Electronic archiving will be provided by the Spon-
sor for post-project deposit and retention of data.
Destruction of essential documents will require au-
thorisation from the Sponsor.
Dissemination policy
On completion of the study a final report will be pre-
pared for Cancer Research Wales.
Findings will be disseminated through various media,
including open-access peer-reviewed publications, na-
tional and international conferences, the programme
web pages, social media, and through an end-of-
programme symposium for key stakeholders. Findings
will also be disseminated to participating practice teams
via a newsletter.
Publications arising directly from the WICKED
programme and authorship on the final trial report will
adhere to the BMJ guidelines on authorship and contri-
bution, based on the International Committee of Med-
ical Journal Editors Recommendations for the Conduct,
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Reporting, Editing, and Publication of Scholarly Work in
Medical Journals (ICMJE) 2013 [57].
Patient and public involvement
The study team recognises that the involvement of those
with lived experiences will be vital in this research. Fur-
thermore, a lay perspective is essential in the develop-
ment and undertaking of research for the promotion of
equality, diversity and transparency. Two patient repre-
sentatives were initially recruited to the WICKED
programme, one of whom has maintained active involve-
ment in the study design, the development of the proto-
col and conduct throughout. Additionally, the trial PPI
has been active in providing feedback on participant-
facing documents. Two more PPI representatives have
been recruited to the TSC through the North Wales
Cancer Forum and have directly relevant experience.
Their perspective as both a patient and a member of the
public will inform the overall supervision of the trial.
Discussion
This study aims to test the feasibility of the ThinkCan-
cer! intervention. The ThinkCancer! study comprises
Work Package 4 (WP4) of a programme of research
called the Wales Interventions and Cancer Knowledge
about Early Diagnosis (WICKED). The intervention will
consist of a workshop aimed at the entire general prac-
tice team, as previous work packages have demonstrated
the value of a whole-practice approach. If the interven-
tion is shown to be feasible, we will proceed with design-
ing a full-scale definitive trial.
One of the key strengths of this intervention is that it
can be iteratively developed throughout the study period,
which will ensure the future definitive trial will adopt an
optimal approach. The design process of the study is
also a strength in that a strong multidisciplinary team
and advisory groups have been involved throughout.
Furthermore, the mixed methods approach will allow
us to capture a variety of data from this complex
intervention. Although recruitment will be challen-
ging, we hope to maximise it by working closely with
various research infrastructures across Wales. Partici-
pating practices will be supported throughout the trial
through regular communication with the research
team, and we will encourage all staff from participat-
ing practices to get in touch should they have any
queries or concerns about the study. We acknowledge
that interventions aiming to increase cancer referrals
bring with them a risk of over-diagnosis and over-
investigation of patients. However, safety netting can
minimise the risk of harm by ensuring referrals are
appropriate [7, 29, 32].
Although safety-netting has garnered more attention in
recent years, there currently are no recommendations on
how best to do it [31]. To our knowledge, there are no in-
terventions targeting primary care with a focus on safety
netting. In addition, involving the entire practice is a
relatively novel approach, with great potential benefit.
This study encompasses a multicomponent and com-
plex behavioural change intervention comprising a
multidimensional, interactive, tailored and whole-
practice approach, which is timely and needed to op-
timise primary care approaches to the timely diagno-
sis of cancer.
Trial status
The trial is currently open for recruitment.
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